Targeted agents, including rituximab, belimumab, and thrombopoietin receptor agonists (TPO-RAs), have been used in small studies, but their overall effectiveness in SLE-associated refractory ITP has not been comprehensively evaluated. The gene discussed is TPO; the disease is systemic lupus erythematosus.